Decreased interleukin-20 level in patients with systemic sclerosis: are they related with angiogenesis?

Basit Öğe Kaydı
dc.contributor.authorAydogdu, Erkan
dc.contributor.authorPamuk, Omer Nuri
dc.contributor.authorDonmez, Salim
dc.contributor.authorPamuk, Gulsum Emel
dc.date.accessioned2024-06-12T11:03:55Z
dc.date.available2024-06-12T11:03:55Z
dc.date.issued2013
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIn this study, we aimed to evaluate the relation between angiogenesis indicators and T helper 17 cytokine group in patients with systemic sclerosis (SSc) which is a disease characterized by impaired angiogenesis and autoimmune response. In our study, patients with SSc are compared with patients with primary Raynaud's phenomenon (RP) and healthy controls. Forty SSc patients, 18 primary RP cases, and 20 healthy controls were included in our study. The demographic and clinical features of patients with SSc were recorded. The serum levels of vascular endothelial growth factor (VEGF), vascular endothelial (VE)-cadherin, interleukin (IL)-20, IL-22, and IL-23 were assessed. In the SSc group, IL-20 level was significantly lower than in both primary RP group and controls (p values < 0.001). VE-cadherin level in SSc was significantly higher than in primary RP (p = 0.016). The IL-22 and IL-23 and VEGF levels of SSc, primary RP, and control groups were similar (p values > 0.05). In SSc patients, IL-23 correlated negatively with VEGF (r = -0.36, p = 0.025) and positively with VE-cadherin (r = 0.55, p < 0.001). IL-20 levels in SSc patients correlated with disease duration (r = 0.32, p = 0.044). SSc patients with limited involvement had significantly higher VE-cadherin levels than SSc patients with diffuse involvement (p = 0.044). We observed that IL-20 which is an IL-10 group angiogenesis indicator was observed to be suppressed in SSc, suggesting abnormal angiogenesis.en_US
dc.description.sponsorshipSociety for Research and Education in Rheumatologyen_US
dc.description.sponsorshipThis project was supported by The Society for Research and Education in Rheumatology. We thank Ahenk Medical Laboratory for their valuable help for our study.en_US
dc.identifier.doi10.1007/s10067-013-2317-0
dc.identifier.endpage1603en_US
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.issue11en_US
dc.identifier.pmid23812620en_US
dc.identifier.scopus2-s2.0-84886279831en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1599en_US
dc.identifier.urihttps://doi.org/10.1007/s10067-013-2317-0
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21836
dc.identifier.volume32en_US
dc.identifier.wosWOS:000325809900005en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofClinical Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInterleukin-20en_US
dc.subjectInterleukin-23en_US
dc.subjectSystemic Sclerosisen_US
dc.subjectTh 17en_US
dc.subjectVE-Cadherinen_US
dc.subjectVascular Endothelial-Cadherinen_US
dc.subjectGrowth-Factoren_US
dc.subjectCellsen_US
dc.subjectPromotesen_US
dc.titleDecreased interleukin-20 level in patients with systemic sclerosis: are they related with angiogenesis?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu